Cargando…

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings

Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mattioli, Flavia, Stampatori, Chiara, Bellomi, Fabio, Scarpazza, Cristina, Capra, Ruggero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492934/ https://www.ncbi.nlm.nih.gov/pubmed/26148120 http://dx.doi.org/10.1371/journal.pone.0131803

Ejemplares similares

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study
por: Mattioli, Flavia, et al.
Publicado: (2015)

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
por: Capra, Ruggero, et al.
Publicado: (2020)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Tele-health in neurology: an indispensable tool in the management of the SARS-CoV-2 epidemic
por: Capra, Ruggero, et al.
Publicado: (2020)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
por: Lo Buono, Viviana, et al.
Publicado: (2022)

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Mattioli, Flavia, et al.
Publicado: (2016)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

The transfer from survey (map-like) to route representations into Virtual Reality Mazes: effect of age and cerebral lesion
por: Carelli, Laura, et al.
Publicado: (2011)

Neurological and cognitive sequelae of Covid-19: a four month follow-up
por: Mattioli, Flavia, et al.
Publicado: (2021)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report
por: De Masi, Roberto, et al.
Publicado: (2022)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Developmental Topographical Disorientation With Concurrent Face Recognition Deficit: A Case Report
por: Rusconi, Maria Luisa, et al.
Publicado: (2021)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Natalizumab alters the TCR repertoire after one year of treatment in four MS patients
por: Michel, Laure, et al.
Publicado: (2011)

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles
por: de la Hera, Belén, et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis
por: Raffel, Joel, et al.
Publicado: (2017)

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
por: Fox, Robert J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o41in0v3le8a5ddu4hsun5rknq